La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (October 2014)

38 slides from La Jolla Pharmaceutical's investor presentation, Oct 14, 2014

  1. Slide 1: Corporate Presentation October 2014

    Corporate Presentation NasdaqCM: LJPC October 2014 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp

  3. Slide 3: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  4. Slide 4: Product Pipeline

    Product Pipeline GCS-100 IV Galectin-3 Inhibitor LJPC-1010 Oral Galectin-3 Inhibitor LJPC-501 Angiotensin II LJPC-401 Hepcidin Other R&D Preclinical IND Phase 1 Phase 2 Phase 3 CKD NASH Underway Completed ESRD Planned H2 2016 H1 2016 HRS CRH H1 2016 4 Early 2015 H2 2016 2b Early 2015 2015 Iron Overl

  5. Slide 5: Overview of LJPC: LJPC-501 for CRH

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  6. Slide 6: LJPC-501 for CRH: Overview

    LJPC-501 for CRH: Overview 6 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to

  7. Slide 7: What Is CRH?

    What Is CRH? Hypotension = low blood pressure that is below the normal perfusion blood pressure (MAP < 60-65 mmHg) • Treated with fluids and catecholamines [epinephrine (adrenaline), norepinephrine (noradrenaline) and dopamine] • Some patients require excessive doses and are found to be resistant 7

  8. Slide 8: Even Short Periods of Hypotension Are Associated with Serious Adverse Events

    Even Short Periods of Hypotension Are Associated with Serious Adverse Events 8 Reference: Anesthesiology 2013, 119;3, 507-515. Predicted probability of (A) acute kidney injury and (B) myocardial injury by lowest mean arterial pressure (MAP) experienced during surgery

  9. Slide 9: What Is LJPC-501?

    What Is LJPC-501? • Proprietary, stable formulation of synthetic angiotensin II • Endogenous eight-amino acid peptide that is central to the renin-angiotensin system ACE inhibitors lower BP by inhibiting synthesis of angiotensin II • Currently being investigated in a Phase 1/2 trial in Hepatorenal S

  10. Slide 10: Angiotensin II Raises Blood Pressure in Hypotensive Pig Model

    Angiotensin II Raises Blood Pressure in Hypotensive Pig Model 10 Reference: Correa,TD, et al. 2014 Crit Care Med. Epubication ahead of print 0 20 40 60 80 100 BL EOP RP 12h RP 24h RP 36h RP 48h M A P (m m H g) Time NE E AT-II norepinephrine enalapril angiotensin II

  11. Slide 11: LJPC-501 Raises Blood Pressure in Hypotensive Pig Model

    11 LJPC-501 Raises Blood Pressure in Hypotensive Pig Model 0 10 20 30 40 50 60 70 80 90 100 Baseline Post-Bleed 30 mg/kg/min p <0.00001 vs. baseline p <0.00001 vs. Post-bleed Baseline Post-bleed 30 mg/kg/min LJPC-501 LJPC-501 MA P (mm H g) MA P (mm H g)

  12. Slide 12: Angiotensin II Raises Blood Pressure in CRH Pilot Trial

    Angiotensin II Raises Blood Pressure in CRH Pilot Trial 12 Reference: Busse, LW, et al. 2014, Critical Care 18(Suppl 1), 160 • Randomized, placebo-controlled, double-blind pilot trial • 20 patients; 10 per arm • Primary efficacy endpoint Catecholamine dose sparing; surrogate for BP effect • Safety a

  13. Slide 13: Norepinephrine Dose Decreases with Angiotensin II

    Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure 13 0 5 10 15 20 25 30 35 40 45 50 Pre2 Pre1 Hr0 Hr1 Hr2 Hr3 Hr4 Hr5 Hr6 Post1 Post2 N or ep in ep hr in e D os e (m cg /m in ) Placebo AT-II Arm Angio dose % of Patients with Rise in BP: Placebo Group 20% vs. Angiot

  14. Slide 14: High Dose Norepinephrine Is Associated with Very Poor Outcome

    High Dose Norepinephrine Is Associated with Very Poor Outcome 14 References: Sviri, S., et al. 2014 J. of Crit Care 29, 157-160. JAMA 2013 Oct23/30 310:1683-1691 • Catecholamines cause cardiac toxicity, digital necrosis and metabolic complications leading to higher mortality 0 10 20 30 40 50 60 70 8

  15. Slide 15: Planned Phase 3 Trial of LJPC-501 in CRH

    Planned Phase 3 Trial of LJPC-501 in CRH 15 • Randomized, placebo-controlled, blinded Phase 3 trial • Patient population: catecholamine-resistant, based on CV SOFA* score • Primary endpoint: blood pressure • Primary endpoint duration: short-term to primary endpoint (hours) • Size: 200-300 patients,

  16. Slide 16: Summary of LJPC-501 in CRH

    Summary of LJPC-501 in CRH 16 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is a high, unmet medical need with no approved therapies • LJPC-501 has been shown to raise blood pressure in a pilot

  17. Slide 17: Overview of LJPC: GCS-100 for CKD

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  18. Slide 18: Galectins and Galectin-3

    Galectins and Galectin-3 18 • Galectin-3 is unique because it has the ability to self-associate (multimerize) up to a pentameric form, allowing it to bind to several receptors at once • Galectin-3 is normally present at low concentration, but is up-regulated in organ failure and cancer; increased le

  19. Slide 19: Galectin-3 and Organ Failure

    Galectin-3 and Organ Failure Epidemiology and Causative Link Clinical Epidemiology • Higher galectin-3 levels in normal individuals are associated with reduced survival1 • Galectin-3 predicts CKD risk in the general population2 • Galectin-3 serum assay is FDA approved to identify patients at risk fo

  20. Slide 20: GCS-100: The Leading Galectin-3 Antagonist

    GCS-100: The Leading Galectin-3 Antagonist Mechanism of Action 20 • GCS-100 is a well-characterized, complex sugar derived from pectin • GCS-100 binds to and neutralizes galectin-3; binding activity is localized to the galactose containing side-branches • Patented manufacturing process required for

  21. Slide 21: Phase 1 Data Validates Galectin-3 as a Target in CKD

    Phase 1 Data Validates Galectin-3 as a Target in CKD r²=0.36191 p=0.003 0 10 20 30 40 50 60 70 80 0 10 20 30 40 50 60 G al -3 n g/ m L eGFR (mL/min/1.73m2) 21 • Single-dose, Phase 1 dose escalation trial complete • 30 mg/m2 MTD • 1/6 patients at 30 mg/m2 experienced reversible, self-limited muscle c

  22. Slide 22: Phase 2a CKD Trial Design

    Phase 2a CKD Trial Design 22 Day 1 Day 57 Dosing, IV PBO or GCS-100 at 1.5 or 30 mg/m2 D -1 D -8 D -2 2 D -2 9 D -3 6 D -4 3 D -5 0 1o Endpoint: eGFR change vs. placebo 2o Endpoint: safety and tolerability Exploratory Endpoints: circulating galectin-3, markers of inflammation, fibrosis and renal inj

  23. Slide 23: Evaluation of Phase 2a Doses Based on PK/PD

    23 Evaluation of Phase 2a Doses 30 mg/m2 Is Too High Based on PK/PD 0 200 400 600 800 1000 1200 1400 1600 0 50 100 150 200 M ol es G C S- 10 0/ M ol e G al -3 Hours post-infusion GCS-100/Gal-3 Ratio 30 mg/m2 Pharmacologic overdose may lead to adverse off-target effects 0 5 10 15 20 25 30 35 40 45 50

  24. Slide 24: Time Course of Activity Consistent with MoA

    -2.5 -2 -1.5 -1 -0.5 0 0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Published CKD Natural Hx Phase 2 Study Placebo Patients Time Course of Activity Consistent with MoA Placebo Group Consistent with Natural Hx of CKD 24 Efficacy Endpoint Also Met at End of Study Time Point (5 Weeks post Last Dose) Placebo Data Co

  25. Slide 25: Safety Data Summary

    Early Terminations • 117 of 121 patients enrolled completed the study Placebo: 40/41 completed; 1 withdrew consent after the first dose 1.5 mg/m2: 41/41 completed 30 mg/m2: 36/39 completed; 1 withdrew consent before the first dose, 1 withdrew consent after the second dose due to scheduling conflict,

  26. Slide 26: GCS-100 CKD Phase 2 Results

    • Primary endpoint reached for 1.5 mg/m2 dose • eGFR effect correlates with change in galectin-3 • Multiple secondary endpoints improved and consistent with primary endpoint analysis • No deaths on study, and no Serious Adverse Events (SAE) and no Grade 3/4 events at 1.5 mg/m2 • No significant adver

  27. Slide 27: Potential Phase 2b Study Design

    • OBJECTIVE Compare efficacy of 3 doses versus placebo • PRIMARY ENDPOINT Sustained improvement in eGFR versus placebo • SECONDARY ENDPOINTS Rate of CV events Potential Phase 2b Study Design 27 • Stage: 3 and 4 • eGFR: high baseline variability excluded • Other: • Etiology of CKD • Biomarkers GCS-10

  28. Slide 28: Overview of LJPC: LJPC-1010 for NASH

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  29. Slide 29: LJPC-1010: Overview

    LJPC-1010: Overview 29 • LJPC-1010 is a more potent and purified derivative of GCS-100 that can be delivered orally • Nonalcoholic steatohepatitis (NASH) is the more serious form of nonalcoholic fatty liver disease (NAFLD), which can lead to liver failure; NASH affects 2 to 5 percent of Americans •

  30. Slide 30: LJPC-1010: Effect in NASH Model

    LJPC-1010: Effect in NASH Model 30 • In a preclinical study of liver fibrosis in the STAM model of NASH, comparing LJPC-1010 to placebo, LJPC-1010 showed a significant reduction (p<0.001) vs. control vehicle in NAFLD activity score • LJPC-1010 showed a significant impact on steatosis (fat accumulati

  31. Slide 31: LJPC-1010: Improves Histology

    LJPC-1010: Improves Histology Phase 1/2 Planned for Early 2015 31 Control Vehicle GCS-100 LJPC-1010 • Next Steps: • Bridging toxicology studies • GMP Manufacturing • Phase 1/2 early 2015

  32. Slide 32: Overview of LJPC: LJPC-401 for Iron Overload

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  33. Slide 33: LJPC-401: Overview

    LJPC-401: Overview • LJPC-401 is a formulation of hepcidin, which is an endogenous peptide hormone that controls and regulates iron metabolism • Several large indications Acquired iron overload – Currently treated with chelators; 50% of patients are intolerant to or fail – Approximately 25,000 patie

  34. Slide 34: LJPC-401: Hepcidin

    LJPC-401: Hepcidin • Hepcidin: the insulin of iron metabolism Regulates iron absorption and disposition in all organs Rapid and sustained lowering of blood iron levels • Next Steps Evaluating SQ formulation Phase 1 2015 34 single 50ug IP injection into a mouse

  35. Slide 35: Overview of LJPC: Financial Position and Milestones

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  36. Slide 36: Financial Position

    Condensed Statement of Cash Flow Data Twelve Months Ended June 30, 2014 (in millions) Cash used for operating activities $7.9 Financial Position 36 Cash resources expected to fund Company through 2016 Condensed Balance Sheet Data As of June 30, 2014 (in millions)* Cash $57.0 Total liabilities $1.1 T

  37. Slide 37: Development Plan

    Development Plan 37 Cash resources through 2016 2017 2015 2016 2014 Today Phase 2b G C S- 10 0 Phase 1 Phase 2a extension Phase 3 LJ P C -5 01 Phase 2/3 Phase 3 Phase 1/2 CRH HRS CKD ESRD IND H2 2014 H2 2015 [DATE] H1 2016 H1 2015 Late 2014 H2 2016 H2 2016 Not Budgeted LJ P C -4 01 Ir on O ve rl oa

  38. Slide 38: Thank You

    / @)Lavolla Thank You

LA Jolla Pharmaceutical — Investor Presentation (October 2014) on 6ix